Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Head and Neck Pathology
Erschienen in: Head and Neck Pathology 3/2017

07.02.2017 | Review Paper

Human Papillomavirus Associated Cancers of the Head and Neck: An Australian Perspective

verfasst von: Marwah Abbas Hassan Aldalwg, Brian Brestovac

Erschienen in: Head and Neck Pathology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Human papillomavirus (HPV) associated head and neck squamous cell carcinomas (HNSCCs), have become a serious global health problem. Despite decreases in HPV-negative HNSCCs, the prevalence of HPV-positive HNSCCs has significantly increased. HPV-positive cancers are associated with superior survival outcomes when compared to HPV-negative cancers, which appears likely to be associated with differences in the molecular pathogenesis of the two diseases. While therapies are still problematic, the current HPV vaccine programs hold a promise for the primary prevention of HPV-related HNSCCs and since Australia was the first to introduce a nationwide HPV vaccine program, it is in a unique position to observe the effects of the vaccine on HNSCCs. This review discusses the epidemiological trends associated with HPV in HNSCC, with reference to the differences between HPV-positive and HPV-negative HNSCCs and the prevention potential of HPV vaccines.
Literatur
1.
Duray A, Lacremans D, Demoulin S, Delvenne P, Saussez S. Prognosis of HPV-positive head and neck cancers: implication of smoking and immunosuppression. Adv Cell Mol Otolaryngol. 2014;2:25717.CrossRef
2.
Morris G, Shukla S. Head and neck cancers in Australia. In: Welfare AIoHa, editor. Canberra: Australian Institute of Health and Welfare, Australian Government; 2014. p. 83.
3.
Ragin CC, Liu JC. Epidemiology of HPV in head and neck cancer: variant strains, discrete protein function; Molecular determinants of head and neck cancer. New York: Springer; 2014. pp. 23–53.
4.
Gupta B, Johnson NW. Systematic review and meta-analysis of association of smokeless tobacco and of Betal Quid without tobacco with incidence of oral cancer in South Asia and the pacific. PLoS ONE. 2014;9(11):1–14.CrossRef
5.
Curado MP, Boyle P. Epidemiology of head and neck squamous cell carcinoma not related to tobacco or alcohol. Curr Opin Oncol. 2013;25(3):229–34.PubMed
6.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
7.
Abogunrin S, Di Tanna GL, Keeping S, Carroll S, Iheanacho I. Prevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysis. BMC Cancer. 2014;14:968.CrossRefPubMedPubMedCentral
8.
Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D’Souza G, et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a national cancer institute state of the science meeting, november 9–10, 2008, Washington, D.C. Head Neck. 2009;31(11):1393–422.CrossRefPubMed
9.
Baez A. Genetic and environmental factors in head and neck cancer genesis. J Environ Sci Health Part C. 2008;26:174–200.CrossRef
10.
Langevin SM, McClean MD, Michaud DS, Eliot M, Nelson HH, Kelsey KT. Occupational dust exposure and head and neck squamous cell carcinoma risk in a population-based case–control study conducted in the greater boston area. Cancer Med. 2013;2(6):978–86.CrossRefPubMedPubMedCentral
11.
Lewis JS. Sinonasal squamous cell carcinoma: a review with emphasis on emerging histological subtypes and the role of human papillomvirus. Head Neck Pathol. 2016;10(1):60–7.CrossRefPubMedPubMedCentral
12.
Attner P, Du J, Näsman A, Hammarstedt L, Ramqvist T, Lindholm J, Marklund L, Dalianis T, Munck-Wikland E. The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer. 2010;126(12):2879–84.PubMed
13.
14.
Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007;110(7):1429–35.CrossRefPubMed
15.
Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–9.CrossRefPubMedPubMedCentral
16.
Bose P, Brockton NT, Dort JC. Head and neck cancer: from anatomy to biology. Int J Cancer. 2013;133(9):2013–23.CrossRefPubMed
17.
Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Nat Cancer Inst. 2000;92(9):709–20.CrossRefPubMed
18.
Scollo M, Winstanley M. Tobacco in Australia: facts and issues. Melbourne: Cancer Council Victoria; 2008.
19.
De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15.CrossRefPubMed
20.
Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W. Human papillomavirus and rising oropharyngeal cancer incidence in the united states. J Clin Oncol. 2011;29(32):4294–301.CrossRefPubMedPubMedCentral
21.
Hong AM, Grulich AE, Jones D, Lee CS, Garland SM, Dobbins TA, Clark JR, Harnett GB, Milross CG, O’Brien CJ. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine. 2010;28(19):3269–72.CrossRefPubMed
22.
23.
Hocking JS, Stein A, Conway EL, Regan D, Grulich A, Law M, Brotherton JML. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer. 2011;104(5):886–91.CrossRefPubMedPubMedCentral
24.
Coughlin A, Qiu S, Underbrink M. Management of human papillomavirus-related head and neck cancer. Curr Probl Dermatol. 2014;45:236-51.PubMed
25.
Oliveira MC, dos Santos Menezes F, da Conceição Andrade M. Epidemiology of HPV in head and neck cancer. INTECH Open Access Publisher; 2012.
26.
Heck JE, Berthiller J, Vaccarella S, Winn DM, Smith EM, Shan’gina O, Schwartz SM, Purdue MP, Pilarska A, Eluf-Neto J. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the international head and neck cancer epidemiology (inhance) consortium. Int J Epidemiol. 2010;39(1):166–81.CrossRefPubMed
27.
Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100(6):407–20.CrossRefPubMed
28.
Rissel C, Badcock PB, Smith AMA, Richters J, de Visser RO, Grulich AE, Simpson JM. Heterosexual experience and recent heterosexual encounters among Australian adults: the second Australian study of health and relationships. Sex Health. 2014;11(5):416–26.CrossRefPubMed
29.
Chung C, Gillison M. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res. 2009;15(22):6758–62.CrossRefPubMed
30.
Mountzios G, Psyrri A. Molecular features and treatment modalities of “classic” versus human papilloma virus-associated head and neck cancer. In: Molecular determinants of head and neck cancer. New York: Springer; 2014. pp. 7–21.
31.
Powell NG, Evans M. Human papillomavirus-associated head and neck cancer: oncogenic mechanisms, epidemiology and clinical behaviour. Diagn Histopathol. 2015;21(2):49–64.CrossRef
32.
Laskar SG, Swain M. HPV positive oropharyngeal cancer and treatment deintensification: how pertinent is it? J Cancer Res Ther. 2015;11(1):6–9.CrossRefPubMed
33.
Gillison ML, Alemany L, Snijders PJF, Chaturvedi A, Steinberg BM, Schwartz S, Castellsagué X: Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine. 2012;30(Suppl 5):F34–54.CrossRefPubMed
34.
Lim MY, Dahlstrom KR, Sturgis EM, Li G. Human papillomavirus integration pattern and demographic, clinical and survival characteristics of patients with oropharyngeal squamous cell carcinoma. Head Neck. 2016;38(8):1139–44.CrossRefPubMed
35.
Psyrri A, DiMaio D. Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol. 2008;5(1):24–31.CrossRefPubMed
36.
Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550–60.CrossRefPubMed
37.
Palma DA, Nichols AC. Human papillomavirus in head and neck cancer. Can Med Assoc J. 2014;186(5):370.CrossRef
38.
Benson E, Li R, Eisele D, Fakhry C. The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. Oral Oncol. 2014;50(6):565–74.CrossRefPubMed
39.
Deng Z, Hasegawa M, Kiyuna A, et al. Viral load, physical status, and E6/E7 mRNA expression of human papillomavirus in head and neck squamous call carcinoma. Head Neck. 2013;35(6):800–8.CrossRefPubMed
40.
Maxwell JH, Grandis JR, Ferris RL. HPV-associated head and neck cancer: unique features of epidemiology and clinical management. Ann Rev Med. 2016;67:91–101.CrossRefPubMed
41.
Lajer CB, Garnæs E, Friis-Hansen L, Norrild B, Therkildsen MH, Glud M, Rossing M, Lajer H, Svane D, Skotte L, Specht L, Buchwald C, Nielsen FC. The role of mirnas in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer. 2012;106(9):1526–34.CrossRefPubMedPubMedCentral
42.
Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157–60.CrossRefPubMedPubMedCentral
43.
Klozar J, Koslabova E, Kratochvil V, Salakova M, Tachezy R. Nodal status is not a prognostic factor in patients with HPV-positive oral/oropharyngeal tumors. J Surg Oncol. 2013;107(6):625–33.CrossRefPubMed
44.
Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 2007;121(8):1813–20.CrossRefPubMed
45.
Gillison M, Harris J, Westra W, Chung C, Jordan R, Rosenthal D, Nguyen-Tan P, Spanos W, Redmond K, Ang K. Survival outcomes by tumor human papillomavirus (HPV) status in stage iii-iv oropharyngeal cancer (opc) in RTOG 0129. ASCO Annu Meet Proc. 2009;27:6003.
46.
Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE. 2013;8(7):e68329.CrossRefPubMedPubMedCentral
47.
Auluck A, Hislop G, Bajdik C, Poh C, Zhang L, Rosin M. Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: the British Columbia experience. Cancer. 2010;116(11):2635–44.PubMed
48.
Colevas AD. Population-based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic status, sex, and race/ethnicity. Head Neck. 2014;36(1):34–42.CrossRefPubMed
49.
Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, Roberts S. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35(5):747–55.CrossRefPubMed
50.
Psychogios G, Alexiou C, Agaimy A, Brunner K, Koch M, Mantsopoulos K, Tomppert A, Iro H. Epidemiology and survival of HPV-related tonsillar carcinoma. Cancer Med. 2014;3(3):652–9.CrossRefPubMedPubMedCentral
51.
Ramqvist T, Mints M, Tertipis N, Näsman A, Romanitan M, Dalianis T. Studies on human papillomavirus (HPV) 16 e2, e5 and e7 mRNA in HPV-positive tonsillar and base of tongue cancer in relation to clinical outcome and immunological parameters. Oral Oncol. 2015;51(12):1126–31.CrossRefPubMed
52.
Näsman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, Ährlund-Richter S, Marklund L, Romanitan M, Lindquist D. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 2009;125(2):362–6.CrossRefPubMed
53.
Burtness B, Golemis E. Overview: the pathobiology of head and neck cancer. New York: Springer; 2014.
54.
Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P. [Stage iii and iv cancers of the oropharynx: results of a randomized study of gortec comparing radiotherapy alone with concomitant chemotherapy]. Bull Cancer. 2000;87:48–53.PubMed
55.
Thibodeau BJ, Geddes TJ, Fortier LE, et al. Gene expression characterization of HPV positive head and neck cancer to predict response to chemoradiation. Head Neck Pathol. 2015;9(3):345–53.CrossRefPubMed
56.
Low GM, Attiga YS, Garg G, Schlegal R, Gallicano GI. Can male vaccination reduce the burden of human papillomavirus-related disease in the United States? Viral Immunol. 2012;25(3):174–86.PubMed
57.
Kenter GG, Welters MJ, Valentijn ARP, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–47.CrossRefPubMed
58.
Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase ii efficacy trial. Lancet Oncol. 2005;6(5):271–8.CrossRefPubMed
59.
Palefsky JM, Giuliano AR, Goldstone S, Moreira Jr ED, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–85.CrossRefPubMed
60.
European Centre for Disease Prevention and Control. Introduction of HPV vaccines in EU countries—an update. Stockholm: ECDC; 2012.
61.
Smith MA, Lew J-B, Walker RJ, Brotherton JML, Nickson C, Canfell K. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine. 2011;29(48):9112–22.CrossRefPubMed
62.
Takes RP, Wierzbicka M, D’Souza G, Jackowska J, Silver CE, Rodrigo JP, Dikkers FG, Olsen KD, Rinaldo A, Brakenhoff RH, Ferlito A. HPV vaccination to prevent oropharyngeal carcinoma: what can be learned from anogenital vaccination programs? Oral Oncol. 2015;51(12):1057–60.CrossRefPubMed
63.
Brotherton JML, Malloy M, Budd AC, Saville M, Drennan KT, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine againt cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observational cohort of young women in Australia. Papillomavirus Res. 2015;1:59–73.CrossRef
64.
Chatterjee A. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines. 2014;13(1):1279–90.CrossRefPubMed
65.
Riethmuller D, Jacquard AC, Lacau St Guily J, et al. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health. 2015;15:453.CrossRefPubMedPubMedCentral
66.
Chaturvedi AK. Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol. 2012;6(Suppl 1):16–24.CrossRefPubMedCentral
Metadaten
Titel
Human Papillomavirus Associated Cancers of the Head and Neck: An Australian Perspective
verfasst von
Marwah Abbas Hassan Aldalwg
Brian Brestovac
Publikationsdatum
07.02.2017
Verlag
Springer US
Erschienen in
Head and Neck Pathology / Ausgabe 3/2017
Elektronische ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-017-0780-7

Weitere Artikel der Ausgabe 3/2017

Head and Neck Pathology 3/2017 Zur Ausgabe

PROCEEDINGS OF THE 2017 NORTH AMERICAN SOCIETY OF HEAD AND NECK PATHOLOGY COMPANION MEETING (SAN ANTONIO, TX)

OSPs and ESPs and ISPs, Oh My! An Update on Sinonasal (Schneiderian) Papillomas

PROCEEDINGS OF THE 2017 NORTH AMERICAN SOCIETY OF HEAD AND NECK PATHOLOGY COMPANION MEETING (SAN ANTONIO, TX)

Intestinal-Type Adenocarcinoma: Classification, Immunophenotype, Molecular Features and Differential Diagnosis

Original Paper

Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma

PROCEEDINGS OF THE 2017 NORTH AMERICAN SOCIETY OF HEAD AND NECK PATHOLOGY COMPANION MEETING (SAN ANTONIO, TX)

Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry

Original Paper

Head and Neck Rhabdomyosarcoma: Clinical and Pathologic Characterization of Seven Cases

Original Paper

Tubulopapillary Hidradenoma-like Tumour of the Mandible: A Case Report and Literature Review

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Open Access 22.02.2024 | Pathologie | Originalien

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

21.02.2024 | Thrombozytopenie | CME

Knochenmarkhistologie bei Zytopenien
Beitrag zur hämatologischen Differenzialdiagnostik

Open Access 21.02.2024 | Fettleber | Originalien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien
Automatische Quantifizierung von Leberverfettung